MedTrace Logo

Liquid Biopsy Collection Study

NCT06068348 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-12-06

No results posted yet for this study

Summary

The purpose of this study is to develop a liquid biopsy approach for detection of circulating tumor cells (CTC) that could be used in place of the more invasive and potentially risky methods of tissue biopsy. The aims of the project are: (a) determine whether the Chaperonin-Containing TCP-1 (CCT) chaperonin can used to identify rare cancer cells in blood, and (b) establish whether the cancer cells detected using the CCT chaperonin for identification have invasive or metastatic potential.

Conditions

  • Chaperonin-Containing TCP-1
  • Circulating Tumor Cells
  • CCT
  • CTC

Sponsors & Collaborators

  • University of Central Florida

    lead OTHER

Principal Investigators

  • Annette Khaled, PhD · University of Central Florida

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-07
Primary Completion
2023-10-31
Completion
2025-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06068348 on ClinicalTrials.gov